Patient-derived xenograft models in cancer therapy: technologies and applications

Y Liu, W Wu, C Cai, H Zhang, H Shen… - Signal Transduction and …, 2023 - nature.com
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

The blood–tumour barrier in cancer biology and therapy

PS Steeg - Nature Reviews Clinical Oncology, 2021 - nature.com
The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …

Prognostic and predictive biomarkers in gliomas

P Śledzińska, MG Bebyn, J Furtak… - International journal of …, 2021 - mdpi.com
Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma

YA Yabo, SP Niclou, A Golebiewska - Neuro-oncology, 2022 - academic.oup.com
Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance

Y Wang, Y Jiang, D Wei, P Singh, Y Yu, T Lee… - Nature biomedical …, 2021 - nature.com
In patients with glioblastoma, resistance to the chemotherapeutic temozolomide (TMZ) limits
any survival benefits conferred by the drug. Here we show that the convection-enhanced …

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine

S Wen, Y Wei, C Zen, W Xiong, Y Niu, Y Zhao - Molecular cancer, 2020 - Springer
Abstract Background N6-methyladenosine (m6A) is the most prevalent messenger RNA
modification in mammalian cells. However, the disease relevant function of m6A on specific …

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

AF Haddad, JS Young, D Amara… - Neuro-oncology …, 2021 - academic.oup.com
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15
months despite an aggressive standard of care that includes surgery, chemotherapy, and …

A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles

JP Straehla, C Hajal, HC Safford… - Proceedings of the …, 2022 - National Acad Sciences
The blood–brain barrier represents a significant challenge for the treatment of high-grade
gliomas, and our understanding of drug transport across this critical biointerface remains …

The many facets of therapy resistance and tumor recurrence in glioblastoma

A Goenka, D Tiek, X Song, T Huang, B Hu, SY Cheng - Cells, 2021 - mdpi.com
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using
chemo-and radio-therapy modestly increases the overall survival of patients; however …

Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology

A Golebiewska, AC Hau, A Oudin, D Stieber… - Acta …, 2020 - Springer
Patient-based cancer models are essential tools for studying tumor biology and for the
assessment of drug responses in a translational context. We report the establishment a large …